This is a much smaller investment than that in yesterday’s news. Mirus’s focus has been in the area of muscular dystrophy. BD
NEW YORK (GenomeWeb News) – Roche said today that it will buy RNAi technologies company Mirus Bio Corporation for $125 million.
Roche plans to divest Mirus’ transfection reagents into a stand-alone business called Mirus Bio LLC, and it expects to offer employees of the Madison, Wis.-based company a transition into respective business units. The Swiss firm intends to retain an RNAi research site at the facilities in Madison.